Educational Sessions
Monday, March 27th
09:00-10:30 - Morgiou
E1: Transplant in non-hematological disorders
Chairs: John Snowden, UK & Francesco Lanza, Italy
09:00-09:30 HSCT for multiple sclerosis and other autoimmune diseases of the nervous system: Harold Atkins, Canada
09:30-10:00 High-dose chemotherapy and autologous stem cell transplantation in breast cancer: a never ending story?
Antony Goncalves, France
10:00-10:30 Stem cell therapy in Rheumatic diseases: Dominique Farge-Bancel, France
11:00-12:30 - Auditorium
E2: Transplant in myeloma
Chairs: Mohamad Mohty, France & William Bensinger, USA
11:00-11:30 The role of upfront auto transplantation in myeloma: William Bensinger, USA
11:30-12:00 Double autotransplant: Jean-Luc Harousseau, France
12:00-12:30 Autotransplantation in elderly patients with multiple myeloma: Joan Bladé, Spain
11:00-12:30 - Amphithéâtre Callelongue
E3: Allogeneic transplantation and gene therapy of inherited disorders
Chairs: Isabelle Thuret, France & Simone Cesaro, Italy
11:00-11:30 Primary Immunodeficiencies: Andrew Gennery, UK
11:30-12:00 Fanconi anemia and other inherited marrow failure disorders: Carlo Dufour, Italy
12:00-12:30 SCID: Marina Cavazzana, France
14:30-16:00 - Auditorium
E4: Transplant in the treatment algorithm of myeloid disorders
Chairs: Norbert Vey, France & Jorge Sierra, Spain
14:30-15:00 Transplant in the treatment algorithm of AML: Jorge Sierra, Spain
15:00-15:30 MDS: Uwe Platzbecker, Germany
15:30-16:00 MPN: Nicolaus Kröger, Germany
14:30-16:00 - Les Goudes 1
E5: Transplant in the treatment algorithm of lymphoma
Chairs: Noël Milpied, France & Silvia Montoto, UK
14:30-15:00 Hematopoietic cell transplantation for T-cell lymphomas: when is the right time to offer it?
Mohamed Kharfan-Dabaja, USA
15:00-15:30 Mantle cell lymphoma: Steve LeGouill, France
15:30-16:00 Rare lymphomas: Peter Dreger, Germany
Tuesday, March 28th
09:00-10:30 - Hall 2
E6: Management of rare early post-transplant complications
Chair: Rafael Duarte, Spain
09:00-09:30 Neurological disorders: Rémy Duléry, France, France
09:30-10:00 TMA: Paul Coppo, France
10:00-10:30 Capillary leak syndrome: Enric Carreras, Spain
09:00-10:30 - Auditorium
E7: GVHD
Chairs: Pierre-Simon Rohrlich, France & Sophie Paczesny, USA
09:00-09:30 Current issues in the management of acute GVHD: Gerard Socié, France
09:30-10:00 Therapy of chronic GVHD: Dawn of targeted intervention: Madan Jagasia, USA
10:00-10:30 Biomarkers to guide GVHD prevention and preemptive therapy: Jan Storek, Canada
11:00-12:30 - Hall 2
E8: Post-transplant therapies for relapse prevention
Chairs: Ibrahim Yakoub-Agha, France & Arnon Nagler, Israel
11:00-11:30 Prophylactic and pre-emptive DLI: Christoph Schmid, Germany
11:30-12:00 FLT3-inhibitors - prior and post-transplant: Richard Schlenk, Germany
12:00-12:30 Hypomethylating agents: Charles Craddock, UK
11:00-12:30 - Les Goudes 1
E9: Some transplant challenges across the world
Chairs: Mahmoud Al-Jurf, Saudi Arabia & Dietger Niederwiesser, Germany
11:00-11:30 HSCT challenges in the Eastern-Mediterranean and Middle-East region: Amir Ali Hamidieh, Iran
11:30-12:00 Setting up a new transplantation program: Mickey Koh, UK/Singapore
12:00-12:30 Emerging infectious threats: Zika virus, Chikungunya, Dengue etc: Jan Styczynski, Poland
Wednesday, March 29th
09:00-10:30 - Les Goudes 2
E10: Late post-transplant complications
Chairs: Bipin Savani, USA & Rafael Duarte, Spain
09:00-09:30 Metabolic syndrome in adults transplanted during childhood: Gérard Michel, France
09:30-10:00 Revaccination post-transplant: Eolia Brissot, France
10:00-10:30 Physical Symptoms: Bipin Savani, USA
09:00-10:30 - Endoume 3
E11: Criteria for donor choice: HLA & beyond
Chairs: Christophe Picard, France & Alejandro Madrigal, UK
09:00-09:30 NGS in HLA-typing: are all mismatches equivalent? Jean Marie Tiercy, Switzerland
09:30-10:00 Permissive mismatches: Katharina Fleischhauer, Germany
10:00-10:30 The non-conventional MHC-I and MICA gene is critically involved in GVHD: Seiamak Bahram, France
11:00-12:30 - Les Goudes 2
E12: Pre and post-transplant interventions
Chairs: Olivier Hermine, France & Hans-Jochem Kolb, Germany
11:00-11:30 Novel antibodies: Ali Bazarbachi, Lebanon
11:30-12:00 Immune checkpoint inhibitors: Ali Bazarbachi, Lebanon
12:00-12:30 Anti-complement drug and allogeneic HSCT: Régis Peffault de Latour, France